News & Updates
Filter by Specialty:
Fulvestrant–sapanisertib combo shows modest benefit in advanced, metastatic breast cancer
Treatment with the combination of fulvestrant plus sapanisertib yields a numerical increase in progression-free survival in patients with ER-positive, HER2-negative advanced or metastatic breast cancer as compared with the use of fulvestrant alone, according to the results of a phase II trial. However, the combination is associated with increased toxicity.
Fulvestrant–sapanisertib combo shows modest benefit in advanced, metastatic breast cancer
22 Mar 2022
IL-6 may mediate psychosomatic syndromes in HF patients
Levels of the proinflammatory cytokine interleukin (IL)-6 seem to be associated with psychosomatic symptoms in patients with heart failure (HF), reports a recent study.
IL-6 may mediate psychosomatic syndromes in HF patients
21 Mar 2022
5 factors predict death in moderate/severe mitral regurgitation
Patients with moderate or severe mitral regurgitation who have been admitted for heart failure exacerbation or has an elevated right atrial pressure, renal dysfunction, anaemia, or lacks a mitral valve intervention suffer a greater risk of all-cause mortality, reveals a study.
5 factors predict death in moderate/severe mitral regurgitation
21 Mar 2022
Age, medication use affect initial response to SARS-CoV-2 vaccines among IBD patients
Most patients with inflammatory bowel disease (IBD) build an initial immune response to SARS-CoV-2 vaccination, but older patients, those treated with antitumour necrosis factor (anti-TNF) and an immunomodulator, and those on corticosteroids may require an additional vaccine dose to achieve better immunity against COVID-19, according to a study.
Age, medication use affect initial response to SARS-CoV-2 vaccines among IBD patients
21 Mar 2022
Oral antibiotics not inferior to IV-only therapy in blood, bone infections
Use of oral antibiotics in the treatment of osteomyelitis, bacteraemia, and infective endocarditis results in shorter hospital stay, has a better safety profile, and appears to be similarly effective when compared to intravenous (IV)-only therapy, a recent study has shown.
Oral antibiotics not inferior to IV-only therapy in blood, bone infections
21 Mar 2022
Abrocitinib effectively manages AD flares
Rescue therapy using the Janus kinase 1 inhibitor abrocitinib combined with topical medicated therapy recaptured efficacy responses and had a favourable safety profile in individuals with moderate-to-severe atopic dermatitis (AD) who experienced flare during the maintenance period of the phase III randomized-withdrawal JADE REGIMEN trial.